{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:12:39Z","timestamp":1760055159140,"version":"build-2065373602"},"reference-count":12,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T00:00:00Z","timestamp":1588896000000},"content-version":"am","delay-in-days":342,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["M\u00e9decine et Maladies Infectieuses"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.medmal.2018.10.005","type":"journal-article","created":{"date-parts":[[2018,11,5]],"date-time":"2018-11-05T09:12:17Z","timestamp":1541409137000},"page":"264-269","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Which antiretrovirals should be prescribed as first-line treatments? Changes over the past 10 years in France"],"prefix":"10.1016","volume":"49","author":[{"given":"P.","family":"Pugliese","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Joly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.A.","family":"Valantin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Cotte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Huleux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Allavena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Reynes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Poizot-Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Bani-Sadr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Cuzin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.medmal.2018.10.005_bib0065","first-page":"205","article-title":"Boosted protease inhibitor-based or nonnucleoside reverse transcriptase-based HAART: is there a best choice for antiretroviral-naive HIV-1 infected patients?","volume":"10","author":"Cuzin","year":"2008","journal-title":"AIDS Rev"},{"key":"10.1016\/j.medmal.2018.10.005_bib0070","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1093\/jac\/dkt533","article-title":"Antiretroviral treatment French guidelines 2013: economics influencing science","volume":"69","author":"Raffi","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.medmal.2018.10.005_bib0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1468-1293.2005.00332.x","article-title":"Determinants of response to first HAART regimen in antiretroviral-naive patients with an estimated time since HIV seroconversion","volume":"7","author":"Thiebaut","year":"2006","journal-title":"HIV Med"},{"year":"2016","series-title":"Prise en charge m\u00e9dicale des personnes vivant avec le VIH 2014","author":"Morlat","key":"10.1016\/j.medmal.2018.10.005_bib0080"},{"key":"10.1016\/j.medmal.2018.10.005_bib0085","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/j.1468-1293.2009.00719.x","article-title":"A large French prospective cohort of HIV-infected patients: the Nadis Cohort","volume":"10","author":"Pugliese","year":"2009","journal-title":"HIV Med"},{"key":"10.1016\/j.medmal.2018.10.005_bib0090","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/QAI.0b013e318157131c","article-title":"Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study","volume":"46","author":"Markowitz","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.medmal.2018.10.005_bib0095","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1016\/S0140-6736(12)60918-0","volume":"379","author":"DeJesus","year":"2012","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.medmal.2018.10.005_bib0100","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1016\/S0140-6736(12)60917-9","article-title":"Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks","volume":"379","author":"Sax","year":"2012","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.medmal.2018.10.005_bib0105","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/S2352-3018(15)00027-2","article-title":"Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study","volume":"2","author":"Molina","year":"2015","journal-title":"Lancet HIV"},{"key":"10.1016\/j.medmal.2018.10.005_bib0110","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S1473-3099(13)70257-3","article-title":"Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial","volume":"13","author":"Raffi","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.medmal.2018.10.005_bib0115","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1056\/NEJMoa1215541","article-title":"Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection","volume":"369","author":"Walmsley","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medmal.2018.10.005_bib0120","doi-asserted-by":"crossref","first-page":"e71473","DOI":"10.1371\/journal.pone.0071473","article-title":"Is clinical practice concordant with the changes in guidelines for antiretroviral therapy initiation during primary and chronic HIV-1 infection? The ANRS PRIMO and COPANA cohorts","volume":"8","author":"Krastinova","year":"2013","journal-title":"PLoS One"}],"container-title":["M\u00e9decine et Maladies Infectieuses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0399077X17305449?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0399077X17305449?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T01:17:24Z","timestamp":1759972644000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0399077X17305449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":12,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S0399077X17305449"],"URL":"https:\/\/doi.org\/10.1016\/j.medmal.2018.10.005","relation":{},"ISSN":["0399-077X"],"issn-type":[{"type":"print","value":"0399-077X"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Which antiretrovirals should be prescribed as first-line treatments? Changes over the past 10 years in France","name":"articletitle","label":"Article Title"},{"value":"M\u00e9decine et Maladies Infectieuses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medmal.2018.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}